Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 7:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Liver Fibrosis/NASH
Interventions
BMS-986171, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chula Vista, California • Cypress, California
Conditions
Diarrhea
Interventions
H10407
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
90Y-DOTA-tyr3-OCTREOTIDE
Radiation
Lead sponsor
O'Dorisio, M S
Other
Eligibility
2 Years to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more
Conditions
Advance Solid Tumors
Interventions
KIVU-107
Drug
Lead sponsor
Kivu Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Interventions
WTX-330
Drug
Lead sponsor
Werewolf Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Conditions
Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
Interventions
Neratinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more
Conditions
Multiple Myeloma
Interventions
PT-112
Drug
Lead sponsor
Promontory Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 4 more
Conditions
B-cell Lymphoma
Interventions
Parsaclisib, Rituximab, Bendamustine, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Tucson, Arizona • Indianapolis, Indiana • Las Vegas, Nevada + 4 more
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy, Calaspargase Pegol-mknl, Cobimetinib
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Conditions
Healthy, Coronary Artery Disease
Interventions
PB127 for Injectable Suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
16
States / cities
Long Beach, California • San Diego, California • Newark, Delaware + 11 more
Conditions
Neoplasms
Interventions
SSR97225
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions
Low-Dose Naltrexone, 1.5mg, Low-Dose Naltrexone, 3.0mg, Low-Dose Naltrexone, 4.5mg, Low-Dose Naltrexone, 6.0mg
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Neoplasms
Interventions
PF-05212384 (also known as PKI-587)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Conditions
Gastroparesis
Interventions
Naronapride, Placebo
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Chula Vista, California • Lomita, California • Clearwater, Florida + 16 more
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding Study of CS19 Expressing ETEC Challenge Strains

NCT00564863
Conditions
Travelers' Diarrhea
Interventions
CS19 expressing ETEC strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Lymphoma
Interventions
Parsaclisib, Hexal, Gazyvaro
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Gilbert, Arizona • La Jolla, California • Fairway, Kansas + 3 more
Completed Phase 1 Interventional Results available

PVSRIPO for Recurrent Glioblastoma (GBM)

NCT01491893
Conditions
GBM, Glioblastoma, Glioma, Malignant Glioma
Interventions
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
71
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Conditions
mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer
Interventions
Gedatolisib, Darolutamide
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Conditions
Pneumococcal Vaccines
Interventions
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
45
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more